Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2109786 | Cancer Genetics | 2015 | 4 Pages |
Abstract
Little is known about MYC dysregulation in myeloid malignancies, and the authors were unable to find published studies that evaluated MYC protein expression in primary cases of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Herein, we describe the clinical, morphologic, immunophenotypic, cytogenetic, and molecular genetic findings in two MDS/AML cases that contained both MYC rearrangement and the JAK2 V617F mutation. We also demonstrate MYC protein expression by immunohistochemistry in both patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Maro Ohanian, Carlos Bueso-Ramos, Chi Young Ok, Pei Lin, Keyur Patel, Mona Lisa Alattar, Joseph D. Khoury, Uri Rozovski, Zeev Estrov, Yang O. Huh, Jorge Cortes, Lynne V. Abruzzo,